Resources

Home > Resources (Page 6)

February 6, 2020 Coronavirus, Innovation, Issues, Multimedia, Radio

https://www.youtube.com/watch?v=so744sbVJ_E Dr. Henry Miller, senior fellow with PRI’s Center for Medical Economics and Innovation, joins PRI's "Next Round" podcast to discuss the Wuhan Coronavirus. We explore a wide variety of topics related to this public health crisis, including how people get the illness and how it is being treated, how the Chinese and U.S. governments are working to combat it, the prospects for the rapid development of a vaccine, how social media disinformation is fueling the crisis, and how concerned Americans...

January 8, 2020 Briefs, Price and Costs, Resources, Studies

As Washington pushes for price caps and government controls to address prescription drug prices, a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute argues that reforming the complex drug supply chain and ending the current drug pricing system that overcharges patients – along with system-wide reforms – are what’s needed to lower America’s health care costs. “Politicians are promoting drug price caps and increased regulation in a futile attempt to increase...

October 25, 2019 Issues, Policy Proposals, Radio

Lars brings on Dr. Henry Miller, a physician, molecular biologist and Senior Fellow at the Pacific Research Institute, and widely published in both scholarly journals and the popular press to discuss this year’s battle against the ever so deadly flu virus. According to Dr. Miller, “Last flu season, which ran from October 2018 until May 2019, caused up to 42.9 million flu illnesses, up to 647,000 hospitalizations and up to 61,200 flu deaths.” Listen below for more. ...

October 8, 2019 Infographics, Price and Costs

var divElement = document.getElementById('viz1570579349519'); var vizElement = divElement.getElementsByTagName('object')[0]; ...

October 2, 2019 Briefs, Industry Trends, Innovation, Price and Costs, Resources

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space][qode_button_v2 target="_self" font_weight="500" hover_effect="" gradient="no" text="DOWNLOAD THE PDF" link="https://medecon.org/wp-content/uploads/2019/10/BiosimilarSavings_web.pdf" color="#ffffff" hover_color="#ffffff" background_color="#a21e2c" hover_background_color="#000000" font_family="arial"][vc_empty_space height="12px"][vc_column_text]Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive originator biologics,” said Dr. Wayne Winegarden, director of PRI’s Center...

July 11, 2019 Briefs, Industry Trends, Price and Costs

Biosimilars have the potential to realize billions in savings for the health care system if reforms are enacted to incent their market share to grow, according to a new issue brief issued today by the Center for Medical Economics and Innovation at the California-based, free-market think tank, the Pacific Research Institute. “Biosimilars are innovative medications that can treat patients at lower costs,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation and author of the issue brief. ...

June 26, 2019 Price and Costs, Studies, Value

A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies “Gene therapies have the potential to cure a wide array of difficult-to-treat diseases, including Alzheimer’s Disease, autism, cystic fibrosis, HIV, and cancer, among others” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics...

June 12, 2019 Briefs, Issues, Resources, Studies

The World Health Organization (WHO) is advocating that the price of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical Economics and Innovation at the non-partisan Pacific Research Institute. “Cancer medications have revolutionized treatment, and it is unfortunate if the WHO’s flawed analysis jeopardizes patients’ access to these life-saving medicines” says...